SCHEMBL5630969

SCHEMBL5630969

O=C(O)CC1CCc2c(sc3ncnc(Cl)c23)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 4/20 0.51
CSNK2B P67870 4/20 0.51
CSNK2A1 P68400 4/20 0.51
LIMK1 P53667 5/20 0.47
ALDH1A1 P00352 3/20 0.46
LMNA P02545 1/20 0.46
KDM4E B2RXH2 2/20 0.45
HTT P42858 2/20 0.45
TSHR P16473 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
CYP2C19 P33261 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PRNP P04156 1/20 0.42
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14459798 0.85 LIMK1 (0.54) CSNK2A2CSNK2BCSNK2A1LIMK1ALDH1A1
SCHEMBL23254239 0.84 ALDH1A1 (0.47) CSNK2A2CSNK2BCSNK2A1LIMK1ALDH1A1
SCHEMBL10343608 0.83 HTT (0.63) CSNK2A2CSNK2BCSNK2A1LIMK1ALDH1A1
SCHEMBL19523758 0.83 HTT (0.63) CSNK2A2CSNK2BCSNK2A1LIMK1ALDH1A1
SCHEMBL16370982 0.81 LIMK1 (0.59) CSNK2A2CSNK2BCSNK2A1LIMK1ALDH1A1
SCHEMBL16741326 0.81 LIMK1 (0.59) CSNK2A2CSNK2BCSNK2A1LIMK1ALDH1A1
SCHEMBL15534269 0.81 LIMK1 (0.59) CSNK2A2CSNK2BCSNK2A1LIMK1ALDH1A1
SCHEMBL16385041 0.81 LIMK1 (0.59) CSNK2A2CSNK2BCSNK2A1LIMK1ALDH1A1
SCHEMBL23254259 0.81 CSNK2A2 (0.50) CSNK2A2CSNK2BCSNK2A1LIMK1ALDH1A1
SCHEMBL15236713 0.80 ALDH1A1 (0.45) CSNK2A2CSNK2BCSNK2A1LIMK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238701-B2 Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION (US) 2007-07-03 US disclosed
US-20060293322-A1 Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION (US) 2006-12-28 US disclosed
EP-1651652-B1 SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORP (US) 2006-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293322-A1 Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders MKI67, PCNA, MYC CSNK2A2 1481/4885CSNK2B 1875/4885CSNK2A1 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.